Skip to Main Content

INFORMATION FOR

    Diseases of the Respiratory Systems, Phase III

    ARRC Trial

    What is the purpose of this trial?

    The proposed study will be a randomized, double-blinded, placebo-controlled Phase III trial to examine the efficacy of AZM therapy relative to placebo in reducing RSV-related morbidity. Patients will be recruited during acute hospitalization and admission to the ICU at seven pediatric hospitals.

    • Trial with
      University of Alabama at Birmingham
    • Ages
      2 years and younger
    • Gender
      Both

    Contact Information

    For more information about this study, including how to volunteer, contact Michelle Ecarma, Research Coordinator

    Help Us Discover!

    You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

    • Last Updated
      08/12/2024
    • Study HIC
      #2000031702